Cholesterol fractions and apolipoproteins during endometriosis treatment by a gonadotrophin releasing hormone (GnRH) agonist implant or by danazol

A Lemay, André Lemay, Lemay A, Brideau NA, N A Brideau, Natalie‐Anne Brideau, Jean‐Claude Forest, Forest JC, J C Forest, S Dodin, Dodin S, Sylvie Dodin, R Maheux, Rodolphe Maheux, Maheux R
Clinical endocrinology · 1991 · vol. 35(4) , pp. 305–310 · doi:10.1111/j.1365-2265.1991.tb03541.x · PMID:1836425 · W2105951310
article OA: closed CC0 ⤵ 14 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-07, 2026-07-17 ⓘ

Goserelin treatment for endometriosis significantly increased HDL cholesterol fractions, while danazol decreased HDL and increased LDL and apolipoprotein B.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

OBJECTIVE: The evaluation of cholesterol fractions and apoproteins during ovarian suppression by a GnRH agonist implant vs danazol in the treatment of endometriosis. DESIGN: A randomized study in 33 patients comparing goserelin (3.6 mg/4 weeks s.c., n = 20) with danazol (2 x 400 mg/day p.o., n = 13) in patients with a laparoscopic diagnosis of endometriosis and treated for 6 months. MEASUREMENTS: Triglycerides, cholesterol (C), LDL-C, HDL-C subfractions and apoproteins A-1 and B were measured at admission, at months 2, 4 and 6 of treatment and at month 2 post-treatment. RESULTS: After 1 month of therapy, serum oestradiol levels were maintained in the menopausal range with goserelin and in the early follicular phase range with danazol. Goserelin induced a significant elevation in HDL-C (by 31.4%), in HDL2-C (24.6%) and in HDL3-C (45.7%) but no significant change in LDL-C or in ApoA-1 and ApoB. By contrast, danazol caused significant diminutions in HDL-C (23.9%), HDL2-C (56.6%) and ApoA-1 (35.6%). Moreover, danazol increased LDL-C (10.5%) and ApoB (29.0%, P less than 0.05). The lipoprotein changes during goserelin had a favourable effect on the atherogenic index (cholesterol/HDL-C) and ApoA-1/ApoB ratio whereas those of danazol had opposite effects. These changes reverted 2 months after danazol while HDL was still elevated after goserelin. CONCLUSIONS: In relation to cholesterol, goserelin is a safe medication. The significance of temporary adverse changes in cholesterol fractions due to danazol is still unknown.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Apolipoproteins Buserelin Cholesterol, HDL Cholesterol, LDL Danazol Endometriosis Adult Apolipoproteins Buserelin Buserelin Cholesterol, HDL Cholesterol, LDL Danazol Endometriosis Endometriosis Estradiol Estradiol Female Gonadotropin-Releasing Hormone Gonadotropin-Releasing Hormone

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (33)

Cited by (14)

Source provenance

europepmc
last seen: 2026-07-27T06:15:28.040536+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:11:54.876058+00:00
License: CC0 · commercial use OK